Drug Profile
Research Programme: factor XIIIa inhibitors - Curacyte
Latest Information Update: 03 Aug 2007
Price :
$50
*
At a glance
- Originator Curacyte AG
- Class Small molecules
- Mechanism of Action Factor XIII inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Deep vein thrombosis
Most Recent Events
- 07 Jun 2004 Preclinical trials in Deep vein thrombosis in Germany (unspecified route)